Analyst Upgrades

Moderna and Merck Report Positive Phase 3 Results for Personalized Melanoma Vaccine

The interim finding shows the vaccine plus Keytruda reduced recurrence and distant spread in high‑risk, resected melanoma and could prompt regulator talks once full data are released.